Update On Vaginal And Rectal Microbicides for HIV Prevention
Ian M. McGowan, MD, PhD, FRCP
Professor of Medicine
Division of Gastroenterology, Hepatology & Nutrition
University of Pittsburgh, Pittsburgh, PA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2015. All rights reserved.
Ian McGowan is a Professor of Medicine at the University of Pittsburgh School of Medicine. Originally trained in medicine at the University of Liverpool, UK, he also has doctoral degrees from Oxford University, UK in mucosal immunology and the Liverpool University, UK in tropical medicine. Since 1989, he has been involved in clinical and research programs related to sexual health, the diagnosis and management of sexually transmitted infections (including HIV infection), translational research related to the mucosal pathogenesis of HIV infection, and the development of antiretroviral therapy to treat and prevent HIV infection. He is currently the Principal Investigator of the University of Pittsburgh-based Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established in 2006, and renewed in 2013, by the National Institute of Allergy and Infectious Diseases to develop topical microbicides for HIV prevention. This position includes providing oversight for the conduct of Phase 1 through Phase 3 clinical trials of novel microbicides in the US, Sub-Saharan Africa, Thailand, and Peru. Outside of the MTN he has an extensive translational research portfolio focusing on the discovery and development of rectal microbicides and long acting injectable agents for HIV prevention. Dr. McGowan has also provided mentorship to multiple post graduate and post-doctoral candidates embarking on translational research projects in both gastroenterology and HIV prevention.
At the completion of this educational session, learners will:
- Appreciate the process of microbicide development.
- Be aware of the current status of lead vaginal and rectal microbicide candidates.
- Understand the critical path towards product availability for HIV prevention.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
